<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005039</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02319</org_study_id>
    <secondary_id>DFHCC 98-262</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <secondary_id>CDR0000067630</secondary_id>
    <nct_id>NCT00005039</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)</brief_title>
  <official_title>A Phase II Randomized Trial of Recombinant Fowlpox and Recombinant Vaccinia Virus Expressing PSA in Patients With Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase II trial to determine the effectiveness of vaccine therapy in treating&#xD;
      patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made&#xD;
      from a person's prostate cancer cells may make the body build an immune response to kill&#xD;
      tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity and maximum tolerated dose of recombinant fowlpox prostate-specific&#xD;
      antigen (PSA) vaccine in patients with advanced adenocarcinoma of the prostate.&#xD;
&#xD;
      II. Determine whether vaccination with recombinant fowlpox-PSA vaccine is associated with&#xD;
      antitumor activity in these patients.&#xD;
&#xD;
      III. Determine the efficacy of prime and boost regimens using recombinant fowlpox-PSA vaccine&#xD;
      and recombinant vaccinia-PSA vaccine in these patients.&#xD;
&#xD;
      IV. Compare the PSA-specific T-cell response in patients treated with recombinant fowlpox-PSA&#xD;
      vaccine followed by recombinant vaccinia-PSA vaccine vs the same vaccines but in reverse&#xD;
      order.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter, dose-escalation study of recombinant&#xD;
      fowlpox prostate-specific antigen (PSA) vaccine.&#xD;
&#xD;
      SAFETY COHORT: The first cohort of 3 patients receives vaccination with recombinant&#xD;
      fowlpox-PSA vaccine intramuscularly (IM). Treatment repeats every 4 weeks for 3 courses. In&#xD;
      the absence of unacceptable toxicity in the first cohort, the second cohort of 3 patients&#xD;
      receives the same vaccine at the dose level immediately higher than the first cohort dose&#xD;
      level. In the presence of unacceptable toxicity in the first cohort, the second cohort of 3&#xD;
      patients receives the same vaccine at a dose level lower than the first cohort dose level.&#xD;
      The maximum tolerated dose (MTD) is the dose preceding that at which 1 of 6 patients&#xD;
      experiences grade 3 or worse dose-limiting toxicity.&#xD;
&#xD;
      Subsequent patients are assigned to one of two vaccination groups based on prior treatment&#xD;
      with recombinant vaccinia-PSA vaccine:&#xD;
&#xD;
      GROUP A (no prior recombinant vaccinia-PSA vaccine): Patients are randomized to one of two&#xD;
      vaccination arms:&#xD;
&#xD;
      ARM I: Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort&#xD;
      every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine&#xD;
      intradermally every 4 weeks for 2 courses.&#xD;
&#xD;
      ARM II: Patients receive the same vaccines as in arm I but in reverse order.&#xD;
&#xD;
      GROUP B (prior recombinant vaccinia-PSA vaccine): Patients receive treatment as in arm I,&#xD;
      group A.&#xD;
&#xD;
      GROUPS A AND B: Patients with stable or responding disease at 6 months after completion of&#xD;
      vaccination therapy may continue treatment on the group and arm to which they were originally&#xD;
      assigned. Treatment repeats every 6-9 months in the absence of disease progression.&#xD;
&#xD;
      Patients are followed monthly for 6 months and then every 3 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>January 2000</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA response</measure>
    <time_frame>Up to 3 months after the final vaccine dose</time_frame>
    <description>PSA response is assessed at 3 successive monthly determinations, starting 28 days after the final vaccine dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive the same vaccines as in arm I but in reverse order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpox-prostate specific antigen vaccine</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>fowlpox-PSA vaccine</other_name>
    <other_name>recombinant fowlpox-PSA vaccine</other_name>
    <other_name>rF-PSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant vaccinia prostate-specific antigen vaccine</intervention_name>
    <description>Given intradermally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>Prostate Specific Antigen Expressing Vaccinia Virus Vaccine</other_name>
    <other_name>rV-PSA vaccine</other_name>
    <other_name>vaccinia prostate-specific antigen vaccine</other_name>
    <other_name>vaccinia-prostate-specific antigen vaccine</other_name>
    <other_name>VPSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the prostate with evidence of metastatic&#xD;
             disease including any of the following:&#xD;
&#xD;
               -  Lymph node positive and prostate-specific antigen (PSA) at least 10 ng/mL&#xD;
&#xD;
               -  Bone scan positive and PSA at least 10 ng/mL&#xD;
&#xD;
               -  Prior radical prostatectomy with rising PSA and PSA at least 2 ng/mL&#xD;
&#xD;
               -  Prior radiotherapy and PSA at least 10 ng/mL&#xD;
&#xD;
               -  Prior cryosurgery and PSA at least 10 ng/mL&#xD;
&#xD;
                    -  PSA criteria does not apply to patients who are assigned to group B of this&#xD;
                       study and were previously treated on vaccine trial DFCI-96079&#xD;
&#xD;
          -  No symptomatic metastatic disease (no bony pain)&#xD;
&#xD;
          -  Complete HLA typing required&#xD;
&#xD;
          -  Performance status - ECOG 0 or 1&#xD;
&#xD;
          -  WBC greater than 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGPT less than 4 times upper limit of normal&#xD;
&#xD;
          -  Creatinine less than 4.0 mg/dL&#xD;
&#xD;
          -  No altered immune function such as eczema&#xD;
&#xD;
          -  No autoimmune diseases such as the following:&#xD;
&#xD;
               -  Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia&#xD;
&#xD;
               -  Systemic lupus erythematosus, Sj√∂gren's syndrome, or scleroderma&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
               -  Goodpasture's syndrome&#xD;
&#xD;
               -  Addison's disease, Hashimoto's thyroiditis, or active Graves' disease&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No allergy or untoward reaction to prior vaccinia (smallpox) vaccination&#xD;
&#xD;
          -  No hypersensitivity to eggs&#xD;
&#xD;
          -  No prior or concurrent extensive eczema or skin disorders (e.g., extensive psoriasis,&#xD;
             burns, impetigo, or disseminated zoster)&#xD;
&#xD;
          -  No other concurrent serious illness&#xD;
&#xD;
          -  No active infection requiring antibiotics until infection has cleared and antibiotics&#xD;
             have been stopped for at least 3 days&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No close contact or household contact with the following high-risk individuals for at&#xD;
             least 2 weeks after each vaccination:&#xD;
&#xD;
               -  Children under age 5&#xD;
&#xD;
               -  Pregnant or nursing women&#xD;
&#xD;
               -  Individuals with prior or concurrent extensive eczema or other eczematoid skin&#xD;
                  disorders&#xD;
&#xD;
               -  Individuals with other acute, chronic, or exfoliative skin conditions (e.g.,&#xD;
                  atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open&#xD;
                  rashes or wounds)&#xD;
&#xD;
               -  Immunodeficient or immunosuppressed individuals (by disease or therapy) such as&#xD;
                  those with HIV infection&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Endocrine therapy&#xD;
&#xD;
          -  Prior vaccinia (smallpox) immunization required&#xD;
&#xD;
          -  No other concurrent biologic therapy (e.g., interferon or interleukin) for cancer&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
          -  No prior hormonal therapy for metastatic disease&#xD;
&#xD;
          -  Prior neoadjuvant hormonal therapy followed by prostatectomy or radiotherapy allowed&#xD;
&#xD;
          -  Patients previously treated with recombinant vaccinia-PSA vaccine may have hormonal&#xD;
             therapy since discontinuing that treatment (Group B)&#xD;
&#xD;
          -  No concurrent hormonal therapy or steroids&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Endocrine therapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Endocrine therapy&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  At least 3 days since prior antibiotics&#xD;
&#xD;
          -  No concurrent immunosuppressive treatment (e.g., after organ transplantation)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Paul Eder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

